SynthesisPloS one2026
Systematic review of lung function assessment among youth and young adults e-cigarette users: Current tools and emerging methods.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis review focuses on the need to identify the lung function assessment tools used for young EC users. The objectives are to examine the current and emerging methods used in assessing lung function among young EC users, besides identifying the alterations in lung function following EC exposure measured by those tools. METHODOLOGY: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 flow checklist. Six databases (Web of Science, PubMed, Scopus, Taylor & Francis, SAGE, and ScienceDirect) were searched in April 2025 for original articles published between 2016 and 2025. Quality appraisal of the eligible articles was conducted using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Findings were synthesized using Narrative analysis.
resultsA total of 7 studies were included. Spirometry was used in all included studies; however, it is unable to detect subclinical lung alterations, as observed through ventilation-perfusion (V/Q) MRI and fractional exhaled nitric oxide (FeNO). Acute exposure to EC results in a decrease of FEV₁, FVC, PEF, and MEF₇₅ spirometric parameters, as well as reducing FeNO levels, while concurrently increasing exhaled breath temperature (EBT). Besides, an increase in V/Q mismatch and heterogeneity in ventilation is observed, with a reduction in perfusion heterogeneity. Chronic EC exposure causes a reduction in FEV1, PEF, FEV1/FVC, and FEF25-75%, besides an increment of Carboxyhaemoglobin (HbCO) level. The assessment of the lung function post-EVALI in association with EC cessation revealed lung function improvement and increased diffusing capacity of the lung for carbon monoxide (DLCO).
conclusionsSpirometry remains the first-line tool for assessing the lung function of young EC users; however, it often misses early lung dysfunction. Emerging methods (FeNO, DLCO, EBT, MRI, HbCO) increasingly complement this limitation. Tailoring multimodal assessment to exposure context, alongside screening and monitoring programs, may assist in early disease detection and prevent long-term respiratory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.